163 Views

Vulcan Capital invests $40 mln in Scytl

Vulcan Capital has invested $40 million in Scytl, which provides secure online voting and election modernization. Vulcan, the investment management firm that oversees Microsoft co-founder Paul Allen’s portfolio. The investment in Scytl was made from Vulcan’s growth equity fund. Abhishek Agrawal, who heads growth equity investments for Vulcan, will join Scytl’s board.

187 Views

Andreessen Horowitz raises $1.5B fourth fund

Andreessen Horowitz announced the closing of a $1.5 billion fourth fund that will mix growth and early stage investing. In a blog post, Managing Partner Scott Kupor said Andreessen Horowitz Fund IV will capitalize on the growth of the mobile Internet and the decline in startup creation cost to back young companies. Industry sources said the fund will be evenly divided between growth and venture investing. The firm now has $4.2 billion under management.

346 Views

Clever raises $10.3M in Sequoia led Series A

Clever said it raised a $10.3 million Series A round led by Sequoia Capital. The round was joined by Y Combinator founder Paul Graham, Y Combinator President Sam Altman and Deborah Quazzo of GSV Advisors. Sequoia Partner Bryan Schreier will join the board.

170 Views

Aquantia completes $16 mln Series G

Aquantia, a high-speed Ethernet connectivity solution for data centers, mobile and enterprise infrastructure, has completed a series G financing for $16 million. Xilinx led the round and existing investors provided additional capital.

Box appoints healthcare advisors

Box has appointed Aneesh Chopra, the first chief technology officer of the US, and Glen Tullman, former CEO of Allscripts, to serve as special advisors for the company’s healthcare and life sciences practice. Headquartered in Los Altos, CA, Box is backed by Andreessen Horowitz, Bessemer Venture Partners, Draper Fisher Jurvetson, Emergence Capital Partners, General Atlantic, Meritech Capital Partners, NEA, Scale Venture Partners, and U.S. Venture Partners, as well as by strategic investors salesforce.com, SAP Ventures and Intel Ventures.

Ataxion secures Series A Financing from Atlas Venture and Biogen Idec

Ataxion, a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases, has secured Series A financing commitments totaling $17 million from Atlas Venture and Biogen Idec. Based in Cambridge, Massachusetts, the company’s lead program is focused on a group of orphan genetic disorders termed hereditary ataxias.

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups